Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches

International Journal of Antimicrobial Agents

Volumn 43, Issue 1, 2014, Pages 60-67

  Barbour, April M ^a,c   Schmidt, Stephan ^a,d   Zhuang, Luning ^a   Rand, Kenneth ^b   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Ceftobiprole; Pharmacokinetics pharmacodynamics; Time kill curves

Indexed keywords

CEFTOBIPROLE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; MATHEMATICAL COMPUTING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROBABILITY; PROBABILITY OF TARGET ATTAINMENT; TIME KILL CURVE;

CEFTOBIPROLE; PHARMACOKINETICS/PHARMACODYNAMICS; TIME-KILL CURVES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HEALTHY VOLUNTEERS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; MUSCLE, SKELETAL; PLASMA; STAPHYLOCOCCAL INFECTIONS; SUBCUTANEOUS FAT; TIME FACTORS;

EID: 84890805986     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.08.016     Document Type: Article

References (31)

1. D. Andes, and W.A. Craig Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target Antimicrob Agents Chemother 50 2006 1376 1383
2. D. Andes, and W.A. Craig In vivo pharmacodynamic activity of the glycopeptide dalbavancin Antimicrob Agents Chemother 51 2007 1633 1642
3. W.A. Craig, and D.R. Andes In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models Antimicrob Agents Chemother 52 2008 3492 3496
4. J.W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N.C. Punt Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141 Antimicrob Agents Chemother 48 2004 1713 1718
5. T.P. Lodise Jr., R. Pypstra, J.B. Kahn, B.P. Murthy, H.C. Kimko, and K. Bush Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects Antimicrob Agents Chemother 51 2007 2378 2387
6. C. Joukhadar, and M. Muller Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future Clin Pharmacokinet 44 2005 895 913
7. W. Treyaprasert, S. Schmidt, K.H. Rand, U. Suvanakoot, and H. Derendorf Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains Int J Antimicrob Agents 29 2007 263 270
8. A. Barbour, S. Schmidt, S.N. Sabarinath, M. Grant, C. Seubert, and D. Skee Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis Antimicrob Agents Chemother 53 2009 2773 2776
9. E.N. Jonsson, and M.O. Karlsson Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 1999 51 64
10. E.I. Nielsen, A. Viberg, E. Lowdin, O. Cars, M.O. Karlsson, and M. Sandstrom Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments Antimicrob Agents Chemother 51 2007 128 136
11. T. Katsube, Y. Yamano, and Y. Yano Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model J Pharm Sci 97 2008 1606 1614
12. P. Chung, P.J. McNamara, J.J. Campion, and M.E. Evans Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus Antimicrob Agents Chemother 50 2006 2957 2965
13. S. Schmidt, S.N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, and S. Sha Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 5039 5045
14. R. Hope, D.M. Livermore, G. Brick, M. Lillie, and R. Reynolds Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06 J Antimicrob Chemother 62 Suppl 2 2008 ii65 ii74
15. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, and A. Forrest Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 2007 79 86
16. W.A. Craig Does the dose matter Clin Infect Dis 33 Suppl 3 2001 S233 S237
17. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501
18. K.A. Rodvold, D.P. Nicolau, T.P. Lodise, M. Khashab, G.J. Noel, and J.B. Kahn Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole Antimicrob Agents Chemother 53 2009 3294 3301
19. S. Delacher, H. Derendorf, U. Hollenstein, M. Brunner, C. Joukhadar, and S. Hofmann A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans J Antimicrob Chemother 46 2000 733 739
20. P. Liu, M. Muller, M. Grant, B. Obermann, and H. Derendorf Tissue penetration of cefpodoxime and cefixime in healthy subjects J Clin Pharmacol 45 2005 564 569
21. H. Kimko, B. Murthy, X. Xu, P. Nandy, R. Strauss, and G.J. Noel Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections Antimicrob Agents Chemother 53 2009 1228 1230
22. A.K. Meagher, A. Forrest, A. Dalhoff, H. Stass, and J.J. Schentag Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin Antimicrob Agents Chemother 48 2004 2061 2068
23. V.H. Tam, A.N. Schilling, and M. Nikolaou Modelling time-kill studies to discern the pharmacodynamics of meropenem J Antimicrob Chemother 55 2005 699 706
24. E.L. Schuck, A. Dalhoff, H. Stass, and H. Derendorf Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form Infection 33 Suppl 2 2005 22 28
25. Y. Yano, T. Oguma, H. Nagata, and S. Sasaki Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics J Pharm Sci 87 1998 1177 1183
26. T.R. Fritsche, H.S. Sader, and R.N. Jones Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006) Diagn Microbiol Infect Dis 61 2008 86 95
27. P. Hebeisen, I. Heinze-Krauss, P. Angehrn, P. Hohl, M.G. Page, and R.L. Then In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci Antimicrob Agents Chemother 45 2001 825 836
28. R.N. Jones, L.M. Deshpande, A.H. Mutnick, and D.J. Biedenbach In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci J Antimicrob Chemother 50 2002 915 932
29. M.S. Rouse, J.M. Steckelberg, and R. Patel In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin- resistant staphylococci associated with endocarditis and bone and joint infection Diagn Microbiol Infect Dis 58 2007 363 365
30. H.F. Chambers Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 49 2005 884 888
31. S.N. Leonard, C.M. Cheung, and M.J. Rybak Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 52 2008 2974 2976